138 related articles for article (PubMed ID: 17851794)
1. [Application of sandostatin in malignant bowel obstruction].
Li J; Jing ML; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep; 10(5):479-81. PubMed ID: 17851794
[TBL] [Abstract][Full Text] [Related]
2. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
Massacesi C; Galeazzi G
Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
Shima Y; Ohtsu A; Shirao K; Sasaki Y
Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
[TBL] [Abstract][Full Text] [Related]
4. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
Weber C; Zulian GB
Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264
[TBL] [Abstract][Full Text] [Related]
5. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
Matulonis UA; Seiden MV; Roche M; Krasner C; Fuller AF; Atkinson T; Kornblith A; Penson R
J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
[TBL] [Abstract][Full Text] [Related]
6. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I
Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
Peng X; Wang P; Li S; Zhang G; Hu S
World J Surg Oncol; 2015 Feb; 13():50. PubMed ID: 25889313
[TBL] [Abstract][Full Text] [Related]
8. Predictors of adverse surgical outcome in the management of malignant bowel obstruction.
Medina-Franco H; García-Alvarez MN; Ortiz-López LJ; Cuairán JZ
Rev Invest Clin; 2008; 60(3):212-6. PubMed ID: 18807733
[TBL] [Abstract][Full Text] [Related]
9. Octreotide for malignant bowel obstruction: twenty years after.
Mercadante S; Porzio G
Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
Uchino R; Kusano S; Hanada N; Ohara C; Okino T; Yamaguchi K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction.
Zhang Y; Gao Y; Ma Q; Dang C; Wei W; De Antoni F; Rocci R; Chen W
Dig Liver Dis; 2006 Mar; 38(3):188-94. PubMed ID: 16311083
[TBL] [Abstract][Full Text] [Related]
12. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
Penning C; Vecht J; Masclee AA
Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
[TBL] [Abstract][Full Text] [Related]
14. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
[TBL] [Abstract][Full Text] [Related]
15. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
[TBL] [Abstract][Full Text] [Related]
16. Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide.
Berger J; Lester P; Rodrigues L
Am J Hosp Palliat Care; 2016 May; 33(4):407-10. PubMed ID: 25646530
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
[TBL] [Abstract][Full Text] [Related]
18. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
[TBL] [Abstract][Full Text] [Related]
19. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
Watari H; Hosaka M; Wakui Y; Nomura E; Hareyama H; Tanuma F; Hattori R; Azuma M; Kato H; Takeda N; Ariga S; Sakuragi N
Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971
[TBL] [Abstract][Full Text] [Related]
20. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]